KMC Speciality

Which are the latest news on KMC Speciality?

Why is KMC Speciality Hospitals (India) Ltd falling/rising?

As of 18-Jul, KMC Speciality Hospitals (India) Ltd's stock price is slightly down at 134.65, despite a strong year-to-date increase of 77.85%. The recent decline in delivery volume may be affecting investor sentiment, contributing to the minor price drop.

As of 18-Jul, KMC Speciality Hospitals (India) Ltd is experiencing a slight decline in its stock price, currently at 134.65, which reflects a change of -0.35 (-0.26%). Despite this minor drop, the stock has shown strong performance over the longer term, with a year-to-date increase of 77.85% and a one-year increase of 104.60%. <BR><BR>In the short term, the stock has outperformed its sector by 1.04% today and has been on a gaining streak for the past three days, accumulating a total return of 3.05% during this period. Additionally, KMC Speciality is trading above its moving averages across various time frames, indicating a generally positive trend in its price movement.<BR><BR>However, there are signs of falling investor participation, as evidenced by a decrease in delivery volume by 21.69% compared to the five-day average. This decline in trading activity could be contributing to the current price drop, despite the overall positive performance metrics. <BR><BR>In summary, while KMC Speciality Hospitals has shown strong growth over the past year and is currently outperforming its sector, the recent decline in delivery volume may be impacting investor sentiment and contributing to the slight decrease in stock price.

Should I buy, sell or hold KMC Speciality Hospitals (India) Ltd?

How big is KMC Speciality?

As of 10th June, KMC Speciality Hospitals (India) Ltd has a market capitalization of 1,889.00 Cr and reported net sales of 305.76 Cr and net profit of 46.74 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: KMC Speciality Hospitals (India) Ltd has a market capitalization of 1,889.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 305.76 Cr, while the sum of Net Profit for the same period is 46.74 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 164.33 Cr, and Total Assets amount to 286.00 Cr.

Who are in the management team of KMC Speciality?

The management team of KMC Speciality includes S Chandrakumar (Executive Chairman), Selvaraj Manivannan (Managing Director), and several Non-Executive Directors, along with Sushma K as Company Secretary. They are responsible for the company's strategic direction and regulatory compliance.

The management team of KMC Speciality includes the following individuals:<BR><BR>1. **S Chandrakumar** - Executive Chairman & Whole-Time Director<BR>2. **Selvaraj Manivannan** - Managing Director<BR>3. **A Krishnamoorthy** - Non-Executive & Independent Director<BR>4. **S Chenthilkumar** - Non-Executive & Independent Director<BR>5. **N Bala Baskar** - Non-Executive & Independent Director<BR>6. **N Jeyanthei** - Non-Executive & Independent Director<BR>7. **T Senthil Kumar** - Non-Executive & Non-Independent Director<BR>8. **S Vijayabaskaran** - Non-Executive Director<BR>9. **Sushma K** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

Who are the peers of the KMC Speciality?

KMC Speciality's peers include Jeena Sikho, Kovai Medical, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, Shalby, GPT Healthcare, Unihealth Hosp, and Chandan Healthca. KMC Speciality has the highest 1-year return at 75.82%, while Jeena Sikho has the lowest return, and several peers show negative six-month returns.

Peers: The peers of KMC Speciality are Jeena Sikho, Kovai Medical, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, Shalby, GPT Healthcare, Unihealth Hosp, and Chandan Healthca.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Good management risk is found at Kovai Medical. Average management risk is found at Jeena Sikho, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, Shalby, Unihealth Hosp, and Chandan Healthca. Growth is Excellent for Jeena Sikho, Artemis Medicare, Dr Agarwal's Eye, Unihealth Hosp, and Chandan Healthca, while Good growth is noted at KMC Speciality and Indrapr.Medical. Below Average growth is seen at Shalby, and Average growth is found at Kovai Medical. Excellent capital structure is observed at KMC Speciality, Indrapr.Medical, GPT Healthcare, and Unihealth Hosp, while Good capital structure is noted at Kovai Medical, Shalby, and Chandan Healthca.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 75.82%, while Jeena Sikho has the lowest with a return of N/A. KMC Speciality's return significantly exceeds that of Jeena Sikho. Additionally, the six-month return is negative for Jeena Sikho, Indrapr.Medical, Dr Agarwal's Eye, Shalby, and GPT Healthcare.

What does KMC Speciality do?

KMC Speciality Hospitals (India) Ltd is a micro-cap company in the hospital industry, reporting net sales of 82 Cr and a net profit of 15 Cr for March 2026. The company, originally founded in 1982, has a market cap of INR 1,889 Cr and key metrics include a P/E ratio of 41.00 and a return on equity of 22.21%.

Overview:<BR>KMC Speciality Hospitals (India) Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as 'Advanced Medical Care Private Limited' in 1982, converted to a Public Limited Company in 1988, and underwent name changes to 'Seahorse Hospitals Limited' in 1995 and to its current name on October 24, 2008. The latest quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 82 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 15 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap: INR 1,889 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 41.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.14<BR>- Return on Equity: 22.21%<BR>- Price to Book: 8.82<BR><BR>Contact Details:<BR>Address: 6 Royal Road, Cantonment Trichy Tamil Nadu : 620001<BR>Tel: 91-431-4077777<BR>Email: cs.kmcshil@kauveryhospital.com<BR>Website: http://www.kmcspecialityhospital.in

Are KMC Speciality Hospitals (India) Ltd latest results good or bad?

KMC Speciality Hospitals (India) Ltd reported strong Q4 FY26 results, with a net profit of ₹14.63 crore (up 223.67% year-on-year) and revenue growth of 34.99% to ₹82.25 crore, marking the highest quarterly revenue in its history. Overall, the results are very good, indicating robust growth and improved operational efficiency.

KMC Speciality Hospitals (India) Ltd has reported impressive results for Q4 FY26, indicating a strong performance. The company achieved a net profit of ₹14.63 crore, which represents a remarkable year-on-year increase of 223.67%. Additionally, revenue grew by 34.99% year-on-year, reaching ₹82.25 crore, marking the highest quarterly revenue in the company's history.<BR><BR>The operating margin also reached an all-time high of 31.47%, reflecting a significant improvement from the previous year. This margin expansion is a positive indicator of the company's operational efficiency and ability to leverage its expanded facilities effectively. Furthermore, the return on equity (ROE) stands at a healthy 20.10%, demonstrating strong capital efficiency.<BR><BR>Overall, KMC Speciality's latest results are very good, showcasing robust growth in both revenue and profitability, along with improved operational metrics. The company's performance suggests it is well-positioned for continued success in the healthcare sector.

When is the next results date for KMC Speciality Hospitals (India) Ltd?

The next results date for KMC Speciality Hospitals (India) Ltd is 29 May 2026.

The next results date for KMC Speciality Hospitals (India) Ltd is scheduled for 29 May 2026.

Is KMC Speciality technically bullish or bearish?

As of November 21, 2025, the trend is mildly bullish due to daily moving averages, but mixed signals from weekly and monthly indicators suggest underlying weaknesses.

As of 21 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are bullish, while the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The weekly RSI is bearish, which adds to the cautious outlook. Overall, the indicators reflect a mildly bullish sentiment, but with some underlying weaknesses, particularly in the longer-term monthly data.

Is KMC Speciality overvalued or undervalued?

As of November 13, 2025, KMC Speciality is considered undervalued with a PE Ratio of 41.88 and an attractive valuation compared to peers like Apollo Hospitals and Max Healthcare, while also outperforming the Sensex with a 1-week return of 12.88%.

As of 13 November 2025, KMC Speciality has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, especially when compared to its peers in the hospital industry. Key ratios include a PE Ratio of 41.88, an EV to EBITDA of 19.70, and a ROE of 18.51%. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE Ratio of 64.07, while Max Healthcare is even more expensive at 88.67. This suggests that KMC Speciality offers a more favorable valuation relative to its competitors. Additionally, KMC's recent stock performance has outpaced the Sensex, with a 1-week return of 12.88% compared to the Sensex's 1.40%, reinforcing the attractiveness of its current valuation.

How has been the historical performance of KMC Speciality?

KMC Speciality has shown steady growth in net sales and total operating income, reaching 231.60 Cr in March 2025, but faced declines in profit metrics and increased liabilities, indicating potential profitability challenges. Cash flow from operations improved, contributing to a stronger cash position despite negative investing cash flow.

Answer:<BR>The historical performance of KMC Speciality shows a steady growth in net sales, reaching 231.60 Cr in March 2025, up from 177.18 Cr in March 2024 and 155.76 Cr in March 2023. Total operating income has followed a similar upward trend, increasing to 231.60 Cr in March 2025 from 177.18 Cr in the previous year. The company's total expenditure, excluding depreciation, also rose to 174.71 Cr in March 2025, compared to 129.79 Cr in March 2024. Operating profit, excluding other income, improved to 56.89 Cr in March 2025, while profit before tax decreased to 31.60 Cr from 40.56 Cr in March 2024. Profit after tax also saw a decline to 21.43 Cr in March 2025 from 30.38 Cr in March 2024. The earnings per share (EPS) decreased to 1.31 in March 2025 from 1.86 in March 2024. <BR><BR>In terms of assets and liabilities, total assets increased to 286.00 Cr in March 2025 from 263.72 Cr in March 2024, while total liabilities also rose to 286.00 Cr from 263.72 Cr. The company's long-term borrowings increased to 72.33 Cr in March 2025, up from 63.85 Cr in March 2024. Cash flow from operating activities improved to 57.00 Cr in March 2025, compared to 38.00 Cr in March 2024, while cash flow from investing activities showed a negative trend at -50.00 Cr in March 2025. The closing cash and cash equivalents increased to 9.00 Cr in March 2025 from 4.00 Cr in March 2024, indicating a positive cash position despite the fluctuations in profit metrics.<BR><BR>Breakdown:<BR>KMC Speciality has demonstrated consistent growth in net sales, which rose from 102.64 Cr in March 2021 to 231.60 Cr in March 2025. This growth is reflected in the total operating income, which also increased significantly over the years. However, the total expenditure has risen in tandem, leading to an operating profit of 56.89 Cr in March 2025, a notable increase from previous years. Despite this, profit before tax and profit after tax saw declines in March 2025 compared to the previous year, indicating potential challenges in maintaining profitability. The company's total assets and liabilities have both increased, with long-term borrowings rising significantly, suggesting increased leverage. Cash flow from operating activities has improved, contributing to a stronger cash position, even as cash flow from investing activities remains negative. Overall, while KMC Speciality has shown growth in sales and operating income, profitability metrics and rising liabilities warrant close attention.

Who are the top shareholders of the KMC Speciality?

The top shareholder of KMC Speciality is Sri Kauvery Medical Care (India) Limited, holding 75%. D Chitra is the largest individual investor with 1.36%, while individual investors collectively own 22.03% of the shares.

The top shareholders of KMC Speciality are primarily the promoters, with Sri Kauvery Medical Care (India) Limited holding the largest stake at 75%. In terms of public shareholders, D Chitra is the highest individual investor with a holding of 1.36%. Additionally, individual investors collectively hold 22.03% of the shares. There are also four mutual fund schemes and one foreign institutional investor (FII) involved, but their holdings are minimal.

Has KMC Speciality declared dividend?

No Dividend History Available